Implementation of new evidence into hypertension guidelines: The case of the ONTARGET and TRANSCEND trials

Journal of Hypertension

Volumn 27, Issue SUPPL. 2, 2009, Pages

  Grassi, Guido ^a,b   Mancia, Giuseppe ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Angiotensin receptor blockers; Antihypertensive treatment; Blood pressure control; Clinical trials; Guidelines

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACIDIPINE; RAMIPRIL; TELMISARTAN; VALSARTAN;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; META ANALYSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; ARTICLE;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC;

EID: 69449090034     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000354520.67451.1b     Document Type: Review

References (23)

1. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
3. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
4. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372:1174-1183.
5. Yusuf S, Diener HC, Sacco RL, Cotton D,Ounpuu S, Lawton WA,et al., for the PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225-1237.
6. Volpe M, Tocci G, Trimarco B, Rosei EA, Borghi C, Ambrosioni E, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007; 25:1491-1498.
7. Cuspidi C, Ambrosioni E, Mancia G, Pessina AC, Trimarco B, Zanchetti A, APROS Investigators. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens 2002; 20:1307-1314.
8. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762. (Pubitemid 28269185)
9. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363:2049-2051.
10. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J, Heart Outcomes Prevention Evaluation (HOPE) Study. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358:2130-2131.
11. Ambrosini E. Healthcare benefits of very-low-dose combination treatment used in management of hypertension. J Hypertens Suppl 2001; 19:S29-S36.
12. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20:1461-1464.
13. Waeber B, Feihl F, Mancia G. Blood pressure control in Europe. In: Mancia G, Grassi G, Kjeldsen SE, editors. Manual of hypertension of the European Society of Hypertension. London: Informa Healthcare; 2008. pp. 326-333.
14. Mancia G, Pessina AC, Trimarco B, Grassi G, for the SILVIA (Studio Italiano Longitudinale sulla Valutazione della Ipertensione Arteriosa nel 2000) Study Group. Blood pressure control according to new Guidelines targets in low-to high-risk hypertensives managed in specialist practice. J Hypertens 2004; 22:2387-2396.
15. Mancia G, Ambrosini E, Rosei EA, Leonetti G, Trimarco B, Volpe M, for the ForLife study group. Blood pressure control risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens 2005; 23:1575-1581.
16. Mancia G, Parati G, Bilo G, Maronati A, Omboni S, Baurecht H, et al. Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. J Hypertens 2008; 26:374-375.
17. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation office, home and ambulatory blood pressure. Hypertension 2006; 47:846-853.
18. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008; 26:819-824.
19. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006; 114:838-854.
20. Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008; 26:1282-1289.
21. Mancia G. Blood pressure reduction and cardiovascular outcomes: past, present, and future. Am J Cardiol 2007; 100:3J-9J.
22. Williams B, O'Rourke M. Anglo-Scandinavian Cardiac Outcomes Trial. The Conduit Artery Functional Endpoint (CAFE) study in ASCOT. J Hum Hypertens 2001; 15 (Suppl 1):S69-S73.
23. ManciaG,Grassi G. Management ofvery elderly hypertensives: the HYVET study. Aging Clin Exp Res 2008; 20:494-495.